Brief: Tuhura Biosciences Received FDA Orphan Drug Designation For Ifx-2.0
02/02/2026 13:17
Feb 2 (Reuters) - TuHURA Biosciences Inc HURA.O: TUHURA BIOSCIENCES RECEIVED FDA ORPHAN DRUG DESIGNATION FOR IFX-2.0 FOR THE TREATMENT OF STAGE IIB TO STAGE IV CUTANEOUS MELANOMA Source text: ID:nPn8bvB0Ba Further company coverage: HURA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.